ARTICLE | Company News
Avila, Clovis deal
January 30, 2012 8:00 AM UTC
Avila received a $4 million milestone payment from Clovis under a 2010 deal granting Clovis an exclusive, worldwide license to develop and commercialize Avila's EGFR mutant-selective inhibitor (EMSI)...